A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

NCT02773381 · Completed

Last updated 2026-05-28

This clinical trial is testing how a medication called oral semaglutide affects blood sugar, fat levels, appetite, and digestion in people with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 15 people

Who can join Ages 18–75 · all sexes

Timeline Started 2016-06 · est. completion 2018-10

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT02773381 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric emptying in subjects with Type 2 diabetes

Treatments tested

semaglutide Drug

Oral administration once-daily.
placebo Drug

Oral administration once-daily.

Main thing measured	Area under the serum glucose concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02773381 ↗